AI Labs
Insitro
A machine-learning-driven drug discovery company that has raised approximately $800 million in capital (including $150 million from non-dilutive pharma partnerships), and expanded its Eli Lilly collaboration in September 2025 to build ML models predicting small-molecule pharmacological properties. Insitro acquired CombinAbleAI in January 2026 and launched its TherML (Therapeutic Machine Learning) platform, completing a full-stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 57% avg. source confidence
- SynBioBeta / insitro corporate site — insitro expands Lilly collaboration to build ML models predicting small-molecule pharmacology58% source confidence
- insitro corporate site — insitro acquires CombinAbleAI, launches TherML full-stack drug design platform56% source confidence
Dependency Map
What Insitro depends on below, and who depends on Insitro above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Insitro's Timeline
A sourced, dated history of Insitro's key moments — founding to present.
Jan 2018 · Founded
Insitro was founded to apply machine learning to drug discovery and development.
Jan 2026 · Acquires CombinAbleAI, launches TherML platform
Insitro acquired CombinAbleAI and launched its TherML (Therapeutic Machine Learning) platform, completing a full-stack, modality-agnostic drug discovery and design capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics.